Second-line systemic therapy for metastatic colorectal cancer.

CONCLUSIONS: Systemic therapy offers a survival benefit to people with metastatic CRC who did not respond to first-line treatment, especially when targeted agents are combined with conventional chemotherapeutic drugs. Further research is needed to define the optimal regimen and to identify people who most benefit from each treatment.
PMID: 28128439 [PubMed - as supplied by publisher]

Source: Cochrane Database of Systematic Reviews - January 26, 2017 Category: Journals (General) Authors: Mocellin S, Baretta Z, Roqué I Figuls M, Solà I, Martin-Richard M, Hallum S, Bonfill Cosp X Tags: Cochrane Database Syst Rev Source Type: research